Infant nutrition is a lucrative and expanding market in Asia Pacific. Increasing affluence and births spur this growth – the region’s population is expected to grow by 1 billion between now and 2050. However, regulators across Asia Pacific are passing laws to govern infant nutrition production, sales and label claims.
While infant formula is not a pharmaceutical product, regulations demand a higher level of clinical evidence compared to other nutritional products. This has implications for manufacturers across the board on what to sell, where to sell, how to sell.
This report explores these regulatory changes and their impact on product innovation, sales and promotion in the region. It also offers advice to manufacturers on the types of clinical studies needed to validate claims and how to plan and manage these studies to optimize returns.